Alembic receives USFDA final approval for Alcaftadine Ophthalmic Solution, 0.25% (OTC)
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
Alcaftadine Ophthalmic Solution, 0.25% (OTC) is used to temporarily relieve itchy eyes due to pollen, ragweed, grass, animal hair, and dander
US$ 800 million senior secured notes, the largest high yield debut USD bond issuance from India in the last 10 years
Clariant is launching high-performing pharmaceutical ingredients to support the evolution of safe and effective medicines
Sun Pharma will have the exclusive worldwide rights to commercialise Fibromun
Gilead Sciences first launched Lenacapavir under the brand name Sunlenca in the United States and Europe markets in the year 2022
The special financing terms offered by United Imaging and structured by Medikabazaar to Krsnaa Diagnostics underscore the strategic importance of this alliance
Agreement enables access of EU-approved treatment for myotonia symptoms in non-dystrophic myotonic disorders to patients from Argentina and Colombia
India called for stronger investments in health and social equity at G20 Joint Finance-Health Task Force Meeting
Global survey reveals top workforce concerns, evolving strategic priorities, and key technology investment areas for life sciences manufacturers
Subscribe To Our Newsletter & Stay Updated